UBS Group’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $52 | Hold |
1,163
| – | – | ﹤0.01% | 10936 |
|
|
2026
Q2 | $73 | Hold |
1,163
| – | – | ﹤0.01% | 10149 |
|
|
2026
Q1 | $64 | Hold |
1,163
| – | – | ﹤0.01% | 10178 |
|
|
2025
Q4 | $291 | Sell |
1,163
-117
| -9% | -$42 | ﹤0.01% | 10055 |
|
|
2025
Q3 | $397 | Sell |
1,280
-190
| -13% | -$114 | ﹤0.01% | 9695 |
|
|
2025
Q2 | $932 | Sell |
1,470
-1,371
| -48% | -$535 | ﹤0.01% | 9704 |
|
|
2025
Q1 | $582 | Buy |
2,841
+2,747
| +2,922% | +$718 | ﹤0.01% | 9724 |
|
|
2024
Q4 | $41 | Sell |
94
-106
| -53% | -$28 | ﹤0.01% | 9723 |
|
|
2024
Q3 | $28 | Sell |
200
-405
| -67% | -$69 | ﹤0.01% | 9284 |
|
|
2024
Q2 | $125 | Buy |
+605
| New | +$139 | ﹤0.01% | 9131 |
|
|
2023
Q4 | – | Sell |
-3,802
| Closed | -$422 | – | 9715 |
|
|
2023
Q3 | $422 | Buy |
+3,802
| New | +$692 | ﹤0.01% | 8507 |
|
|
2023
Q1 | – | Sell |
-798
| Closed | -$128 | – | 10113 |
|
|
2022
Q4 | $128 | Sell |
798
-1,160
| -59% | -$293 | ﹤0.01% | 10370 |
|
|
2022
Q3 | $0 | Buy |
+1,958
| New | +$506 | ﹤0.01% | 10727 |
|
|
2022
Q1 | – | Sell |
-4,491
| Closed | -$4K | – | 10687 |
|
|
2021
Q4 | $4K | Buy |
+4,491
| New | +$4K | ﹤0.01% | 9532 |
|
UBS Group's NRSNW Position: Q3 2026 in Review
UBS Group held its NeuroSense Therapeutics Warrant (NRSNW) position steady in Q3 2026 at 1,163 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #10936.
UBS Group first reported a position in NRSNW in Q4 2021 and has held it in 14 quarters since. The position peaked at $4K in Q4 2021. 1 fund tracked by Wall St. Rank holds NRSNW as of Q3 2026.
- UBS Group held 1,163 shares of NeuroSense Therapeutics Warrant worth $52 as of Q3 2026.
- UBS Group left its NeuroSense Therapeutics Warrant share count unchanged in Q3 2026.
- NeuroSense Therapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10936 holding.
- UBS Group first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 14 quarters since.
- UBS Group's NeuroSense Therapeutics Warrant position peaked at $4K in Q4 2021.
- 1 fund tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.